Document is current

Article History

Received: 5 March 2022

Accepted: 21 June 2022

First Online: 29 July 2022

Declarations

:

: Antonio Jimeno reports no relevant conflicts, he owns stock/options on Champions Oncology and Suvica. Antonio Jimeno’s institution has contracts for trials where he is local principal investigator with Pfizer Inc., Merck, SQZ, Moderna, Iovance, Khar Biopharma, DebioPharm, Cantargia and Sanofi. Mateusz Opyrchal has research support from Pfizer and Eli Lilly and is a consultant for AstraZeneca Pharmaceuticals and Novartis. Michelle Redman, Wing-Kai Chan, Hui Wang, Doug Kramer, Rudolf Kwan, David Cutler, Jay Zhi are current or prior Athenex Inc. employees. Dough Kramer also owns stock/options on Athenex Inc. Rudolf Kwan is also shareholder of Athenex Inc., Merck, and Bristol Myers Squibb. Christos Fountzilas reports no relevant conflicts, he has institutional research support from Pfizer and Taiho Oncology outside of the scope of submitted work. Bradley Corr serves on advisory boards for GlaxoSmithKline, Merck, AstraZeneca Pharmaceuticals, Novocure, Immunogen and has research funding from Clovis. Marwan Fakih has research support (institutional) from Amgen, Inc., AstraZeneca Pharmaceuticals, Bristol Myers Squibb, Genentech, Novartis Oncology, and Verastem; is a consultant for Bayer Corporation, HalioDx, Mirati Therapeutics, Inc., Pfizer, Inc., Taiho Oncology, and Zhuhai Yufan Biotechnology Co., Ltd.; serves in advisory board for Amgen, Inc., Array BioPharma, GlaxoSmithKline, Seattle Genetics, Inc.; speakers bureau for Amgen, Inc. and Guardant360. Jennifer R. Diamond reports research funding from Adlai Norte, Takeda, Gilead, Merck, AstraZeneca, Astellas, Abbvie, Bristol Myers Squibb, OnKure, Deciphera, Bayer, Hutchison, Genentech; has consulting role in OnKure Therapeutics, and Gilead; has stock options and leadership role with OnKure Therapeutics. Patrick Boland has research support (institutional) from Amgen, Merck, Macrogenics, and Taiho and has had a consulting role with Bayer, Merck, and Pfizer. The remaining authors report no relevant competing interests.

: All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Institutional Review Boards of all participating institutions (University of Colorado, City of Hope Comprehensive Cancer Center and Roswell Park Comprehensive Cancer Center).

: Informed consent was obtained from all individual participants included in the study or their legal guardians prior to participation in all study-related procedures and treatment.